Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | ARG1 | P05089 | 3/20 | 0.36 |
| ▸ | ARG2 | P78540 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.33 |
| ▸ | ODC1 | P11926 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
| ▸ | ACACA | Q13085 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22009126 | 1.00 | CYP1A2 (0.41) | CYP1A2CYP2D6TP53ARG1ARG2 | |
| SCHEMBL8168353 | 1.00 | CYP1A2 (0.41) | CYP1A2CYP2D6TP53ARG1ARG2 | |
| Hydrochloric Acid SCHEMBL28506784 | 0.87 | CYP1A2 (0.42) | CYP1A2CYP2D6TP53ARG1ARG2 | |
| SCHEMBL497756 | 0.79 | CYP1A2 (0.43) | CYP1A2CYP2D6TP53ARG1ARG2 | |
| SCHEMBL15636111 | 0.77 | — | — | |
| SCHEMBL442847 | 0.77 | — | — | |
| SCHEMBL849765 | 0.77 | — | — | |
| SCHEMBL6265677 | 0.77 | — | — | |
| SCHEMBL594190 | 0.74 | — | — | |
| SCHEMBL574756 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10954537-B2 | Amino acids bearing a norbornene moiety | VALANX BIOTECH GMBH (AT) | 2021-03-23 | — | — | US | disclosed |
| US-20200157586-A1 | NOVEL AMINO ACIDS BEARING A NORBORNENE MOIETY | TECHNISCHE UNIVERSITÄT GRAZ (AT) | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157586-A1 | NOVEL AMINO ACIDS BEARING A NORBORNENE MOIETY | BCAT1, BCAT2, NGLY1 | CYP1A2 3233/4885CYP2D6 3289/4885TP53 1456/4885 |
| US-10954537-B2 | Amino acids bearing a norbornene moiety | BCAT1, BCAT2, DNPEP | CYP1A2 2589/4885CYP2D6 2680/4885TP53 1085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.